Treatment of Refractory Schizophrenia With Riluzole

Conditions

Schizoaffective | Schizophrenia

What is the purpose of this trial?

The proposed study would evaluate the benefits of riluzole add-on treatment to patients with schizophrenia who are already receiving medications, but still experience symptoms. Neuroprotective medication riluzole is currently approved for treatment of amyotrophic lateral sclerosis (Lou Gehrig's disease), a severe neurological illness. Due to its unique mechanism of action, riluzole, if effective in helping the symptoms of schizophrenia, would open novel directions in treatment of schizophrenia.



Participation Guidelines

Age:
18 Years - 65 Years
Gender:
Both

Click here for detailed information about who can participate in this trial.


Sponsor:
Stanley Medical Research Institute
Yale University
Dates:
May 2002
Last Updated:
Jan 20, 2009
Study HIC#:
0201013175

Clinicaltrials.gov ID: NCT00375050